1. Proton pump inhibitors and symptomatic hypomagnesemic hypoparathyroidism.
- Author
-
Fatuzzo P, Portale G, Scollo V, Zanoli L, and Granata A
- Subjects
- Aged, Biomarkers blood, Cerebellar Diseases chemically induced, Cerebellar Diseases diagnosis, Dietary Supplements, Drug Substitution, Humans, Hypocalcemia blood, Hypocalcemia chemically induced, Hypocalcemia diagnosis, Hypokalemia blood, Hypokalemia chemically induced, Hypokalemia diagnosis, Hypoparathyroidism blood, Hypoparathyroidism diagnosis, Hypoparathyroidism therapy, Male, Pantoprazole, Proton Pump Inhibitors administration & dosage, Pyrrolidonecarboxylic Acid administration & dosage, Ranitidine administration & dosage, Seizures chemically induced, Seizures diagnosis, Treatment Outcome, 2-Pyridinylmethylsulfinylbenzimidazoles adverse effects, Hypoparathyroidism chemically induced, Magnesium blood, Proton Pump Inhibitors adverse effects
- Abstract
Hypomagnesemia is a common but often overlooked problem in hospitalized patients. Unrecognized hypomagnesemia can cause serious complications. The association of hypokalemia and hypocalcemia is strongly evocative of a magnesium deficiency. Research into the causes of hypomagnesemia is imperative, as it will definitely change the approach, treatment and prognosis. We report the case of a 65-year-old man with chronic hypocalcemia and hypokalemia associated with cerebellar syndrome, a solitary seizure and cerebellar hyperintensities on magnetic resonance imaging. After the detection and treatment of hypomagnesemia with oral supplements of magnesium and the replacement of pantoprazole with ranitidine, we observed immediate relief of the symptoms. In conclusion, in clinical practice, magnesium depletion should be investigated in elderly patients with hypocalcemia treated with proton pump inhibitors for many years, in particular in the presence of neurological disorders.
- Published
- 2017
- Full Text
- View/download PDF